Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients. (PubMed, Bone Marrow Transplant) - Oct 24, 2025 - "Clinical data and recent FDA/EMA approval of letermovir in children are also providing a breakthrough in pediatric CMV disease prevention. Pre-emptive treatment remains the preferred approach in case of clinically significant CMV infection in both adults and children; meanwhile, new available options such as maribavir and broader application of viral-specific T-cells represent valid strategies for the management of refractory/resistant CMV infection, offering a less-toxic therapeutic alternative to conventional, still effective, antivirals."
Journal • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Transplantation
|
|
Federica Galaverna; Jan Styczynski; Per Ljungman
|